Decreased Tenofovir Diphosphate Concentrations in a Transgender Female Cohort: Implications for Human Immunodeficiency Virus Preexposure Prophylaxis

被引：42

作者：

Cottrell, Mackenzie L. ^{[1
]}

Prince, Heather M. A. ^{[2
]}

Schauer, Amanda P. ^{[1
]}

Sykes, Craig ^{[1
]}

Maffuid, Kaitlyn ^{[1
]}

Poliseno, Amanda ^{[1
]}

Chun, Tae-Wook ^{[3
]}

Huiting, Erin ^{[3
]}

Stanczyk, Frank Z. ^{[4
]}

Peery, Anne F. ^{[5
]}

Dellon, Evan S. ^{[5
]}

Adams, Jessica L. ^{[6
,7
]}

Gay, Cindy ^{[2
]}

Kashuba, Angela D. M. ^{[1
,2
]}

机构：

[1] Univ N Carolina, Eshelman Sch Pharm, Div Pharmacotherapy & Expt Therapeut, Chapel Hill, NC 27515 USA

[2] Univ N Carolina, Div Infect Dis, Sch Med, Chapel Hill, NC 27515 USA

[3] NIAID, HIV Immunovirol Unit, 9000 Rockville Pike, Bethesda, MD 20892 USA

[4] Univ Southern Calif, Keck Sch Med, Los Angeles, CA 90007 USA

[5] Univ N Carolina, Sch Med, Div Gastroenterol & Hepatol, Chapel Hill, NC 27515 USA

[6] Univ Sci, Philadelphia Coll Pharm, Philadelphia, PA USA

[7] Cooper Univ Hosp, Early Intervent Program, Camden, NJ USA

来源：

CLINICAL INFECTIOUS DISEASES | 2019年 / 69卷 / 12期

基金：

美国国家卫生研究院;

关键词：

transgender; preexposure prophylaxis; lower gastrointestinal tract; HIV; feminizing hormone therapy; HIV; WOMEN; NUCLEOTIDE;

D O I：

10.1093/cid/ciz290

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Feminizing hormone therapy (FHT) may interact with human immunodeficiency virus preexposure prophylaxis (PrEP). We found that transgender women who took FHT exhibited a 7-fold lower rectal tissue ratio of PrEP's active metabolites vs competing deoxynucleotides compared to cisgender women and men (P = .03) that inversely correlated with estradiol (rho = -0.79; P < .05). Thus, FHT may negatively impact PrEP efficacy.

引用

页码：2201 / 2204

页数：4

共 15 条

[1] Worldwide burden of HIV in transgender women: a systematic review and meta-analysis [J].

Baral, Stefan D. ;

Poteat, Tonia ;

Stromdahl, Susanne ;

Wirtz, Andrea L. ;

Guadamuz, Thomas E. ;

Beyrer, Chris .

LANCET INFECTIOUS DISEASES, 2013, 13 (03) :214-222

[2] FEM-PrEP: Adherence Patterns and Factors Associated With Adherence to a Daily Oral Study Product for Pre-exposure Prophylaxis [J].

Corneli, Amy L. ;

Deese, Jennifer ;

Wang, Meng ;

Taylor, Doug ;

Ahmed, Khatija ;

Agot, Kawango ;

Lombaard, Johan ;

Manongi, Rachel ;

Kapiga, Saidi ;

Kashuba, Angela ;

Van Damme, Lut .

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2014, 66 (03) :324-331

[3] A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine [J].

Cottrell, Mackenzie L. ;

Yang, Kuo H. ;

Prince, Heather M. A. ;

Sykes, Craig ;

White, Nicole ;

Malone, Stephanie ;

Dellon, Evan S. ;

Madanick, Ryan D. ;

Shaheen, Nicholas J. ;

Hudgens, Michael G. ;

Wulff, Jacob ;

Patterson, Kristine B. ;

Nelson, Julie A. E. ;

Kashuba, Angela D. M. .

JOURNAL OF INFECTIOUS DISEASES, 2016, 214 (01) :55-64

[4] Estrogen receptor-1 is a key regulator of HIV-1 latency that imparts gender-specific restrictions on the latent reservoir [J].

Das, Biswajit ;

Dobrowolski, Curtis ;

Luttge, Benjamin ;

Valadkhan, Saba ;

Chomont, Nicolas ;

Johnston, Rowena ;

Bacchetti, Peter ;

Hoh, Rebecca ;

Gandhi, Monica ;

Deeks, Steven G. ;

Scully, Eileen ;

Karn, Jonathan .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2018, 115 (33) :E7795-E7804

[5] HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial [J].

Deutsch, Madeline B. ;

Glidden, David V. ;

Sevelius, Jae ;

Keatley, Joanne ;

McMahan, Vanessa ;

Guanira, Juan ;

Kallas, Esper G. ;

Chariyalertsak, Suwat ;

Grant, Robert M. .

LANCET HIV, 2015, 2 (12) :E512-E519

[6] Effects of Cross-Sex Hormone Treatment on Transgender Women and Men [J].

Deutsch, Madeline B. ;

Bhakri, Vipra ;

Kubicek, Katrina .

OBSTETRICS AND GYNECOLOGY, 2015, 125 (03) :605-610

[7] Natural Substrate Concentrations Can Modulate the Prophylactic Efficacy of Nucleotide HIV Reverse Transcriptase Inhibitors [J].

Garcia-Lerma, J. Gerardo ;

Aung, Wutyi ;

Cong, Mian-er ;

Zheng, Qi ;

Youngpairoj, Ae S. ;

Mitchell, James ;

Holder, Angela ;

Martin, Amy ;

Kuklenyik, Susan ;

Luo, Wei ;

Lin, Carol Yen-Chin ;

Hanson, Debra L. ;

Kersh, Ellen ;

Pau, Chou-Pong ;

Ray, Adrian S. ;

Rooney, James F. ;

Lee, William A. ;

Heneine, Walid .

JOURNAL OF VIROLOGY, 2011, 85 (13) :6610-6617

[8]

Hiransuthikul A, 2018, AIDS2018

[9] The 5′-nucleotidases as regulators of nucleotide and drug metabolism [J].

Hunsucker, SA ;

Mitchell, BS ;

Spychala, J .

PHARMACOLOGY & THERAPEUTICS, 2005, 107 (01) :1-30

[10] Specific Inhibition of HIV Infection by the Action of Spironolactone in T Cells [J].

Lacombe, Benoit ;

Morel, Marina ;

Margottin-Goguet, Florence ;

Ramirez, Bertha Cecilia .

JOURNAL OF VIROLOGY, 2016, 90 (23) :10972-10980

← 1 2 →